Edesa Biotech, Inc.
EDSANASDAQHealthcare● Active
$5.37
$-0.09(-1.65%)
Market Cap$47749772
P/E Ratio—
52W High$20.32
52W Low$0.72
Edesa Biotech, Inc. (EDSA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EDSA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.49
Est. -$0.24 · -104.2%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
EDSA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.63 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.24 | -$0.49 | -104.2% | — | — | — |
| — Q1 FY2026 | Feb 13, 2026 | -$0.28 | -$0.28 | +0.0% | — | — | — |
| ▼ Q4 FY2025 | Dec 12, 2025 | -$0.27 | -$0.32 | -18.5% | — | — | — |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.26 | -$0.25 | +3.9% | — | — | — |
| — Q2 FY2025 | May 14, 2025 | -$0.30 | -$0.30 | +0.0% | — | — | — |
| ▼ Q1 FY2025 | Feb 14, 2025 | -$0.31 | -$0.48 | -54.8% | — | — | — |
| ▲ Q4 FY2024 | Dec 13, 2024 | -$0.54 | -$0.29 | +46.3% | — | — | — |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.63
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.49
EPS Est.
-$0.24
EPS Surpr.
-104.2%
Revenue
—
Q1 FY2026
Feb 13, 2026
EPS Actual
-$0.28
EPS Est.
-$0.28
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Dec 12, 2025Miss
EPS Actual
-$0.32
EPS Est.
-$0.27
EPS Surpr.
-18.5%
Revenue
—
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.25
EPS Est.
-$0.26
EPS Surpr.
+3.9%
Revenue
—
Q2 FY2025
May 14, 2025
EPS Actual
-$0.30
EPS Est.
-$0.30
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Feb 14, 2025Miss
EPS Actual
-$0.48
EPS Est.
-$0.31
EPS Surpr.
-54.8%
Revenue
—
Q4 FY2024
Dec 13, 2024Beat
EPS Actual
-$0.29
EPS Est.
-$0.54
EPS Surpr.
+46.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $-0.65 | $-0.65 | $-0.65 | 1 |
| Q2 FY2026 | $-0.63 | $-0.63 | $-0.63 | 1 |
| Q1 FY2026 | $-0.26 | $-0.26 | $-0.26 | 1 |
| Q4 FY2025 | $-0.56 | $-0.53 | $-0.47 | 2 |
| Q3 FY2025 | $-0.28 | $-0.27 | $-0.26 | 2 |
| Q4 FY2020 | $-1.47 | $-1.47 | $-1.47 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2020 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -104.2% | $15.24 | $14.61 | -4.13% |
| ▲ Q1 FY2026 | Feb 13, 2026 | +0.0% | $1.00 | $1.02 | +2.51% |
| ▼ Q4 FY2025 | Dec 12, 2025 | -18.5% | $1.77 | $1.74 | -1.69% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +3.9% | $2.09 | $2.12 | +1.44% |
| ▲ Q2 FY2025 | May 14, 2025 | +0.0% | $2.00 | $2.03 | +1.50% |
| ▼ Q1 FY2025 | Feb 14, 2025 | -54.8% | $3.25 | $2.69 | -17.23% |
| ▲ Q4 FY2024 | Dec 13, 2024 | +46.3% | $1.80 | $1.94 | +7.78% |
| ▲ Q3 FY2024 | Aug 9, 2024 | +10.3% | $5.12 | $4.84 | -5.47% |
Q2 FY2026-4.13%
Report Date
May 14, 2026
EPS Beat/Miss
-104.2%
Price Before
$15.24
Price After
$14.61
Q1 FY2026+2.51%
Report Date
Feb 13, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.00
Price After
$1.02
Q4 FY2025-1.69%
Report Date
Dec 12, 2025
EPS Beat/Miss
-18.5%
Price Before
$1.77
Price After
$1.74
Q3 FY2025+1.44%
Report Date
Aug 8, 2025
EPS Beat/Miss
+3.9%
Price Before
$2.09
Price After
$2.12
Q2 FY2025+1.50%
Report Date
May 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.00
Price After
$2.03
Q1 FY2025-17.23%
Report Date
Feb 14, 2025
EPS Beat/Miss
-54.8%
Price Before
$3.25
Price After
$2.69
Q4 FY2024+7.78%
Report Date
Dec 13, 2024
EPS Beat/Miss
+46.3%
Price Before
$1.80
Price After
$1.94
Q3 FY2024-5.47%
Report Date
Aug 9, 2024
EPS Beat/Miss
+10.3%
Price Before
$5.12
Price After
$4.84
Avg Beat Reaction+1.55%
Avg Miss Reaction-7.68%
Beat Rate5 / 8 quarters
Largest Move-17.23% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EDSA ends December
Edesa Biotech, Inc. (EDSA) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.49 — missing the analyst consensus of $-0.24 by -104.2%. The next EDSA earnings date is expected around September 1, 2026.
Each quarter, investors track EDSA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EDSA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EDSA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EDSA earnings · 5 questionsEdesa Biotech, Inc.'s next earnings report is expected around September 1, 2026. EDSA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EDSA historically reports after market close (AMC).
EDSA earnings datewhen is EDSA earningsEDSA next earnings datewhen does EDSA report earningsEDSA earnings calendar
▸ Source: FMP · Edesa Biotech, Inc. SEC filings · US GAAP · Edesa Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026